Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.76
AMEX:PLX's Cash to Debt is ranked lower than
84% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. AMEX:PLX: 0.76 )
Ranked among companies with meaningful Cash to Debt only.
AMEX:PLX' s Cash to Debt Range Over the Past 10 Years
Min: 0.51  Med: No Debt Max: No Debt
Current: 0.76
Equity to Asset -0.10
AMEX:PLX's Equity to Asset is ranked lower than
93% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMEX:PLX: -0.10 )
Ranked among companies with meaningful Equity to Asset only.
AMEX:PLX' s Equity to Asset Range Over the Past 10 Years
Min: -1.15  Med: -0.09 Max: 0.8
Current: -0.1
-1.15
0.8
F-Score: 4
Z-Score: -3.72
M-Score: 1.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 1108.24
AMEX:PLX's Operating margin (%) is ranked higher than
99% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. AMEX:PLX: 1108.24 )
Ranked among companies with meaningful Operating margin (%) only.
AMEX:PLX' s Operating margin (%) Range Over the Past 10 Years
Min: -8239.43  Med: -676.52 Max: 1108.24
Current: 1108.24
-8239.43
1108.24
Net-margin (%) -1710.75
AMEX:PLX's Net-margin (%) is ranked lower than
82% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. AMEX:PLX: -1710.75 )
Ranked among companies with meaningful Net-margin (%) only.
AMEX:PLX' s Net-margin (%) Range Over the Past 10 Years
Min: -8103.09  Med: -643.26 Max: 1329.9
Current: -1710.75
-8103.09
1329.9
ROA (%) 63.81
AMEX:PLX's ROA (%) is ranked higher than
99% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. AMEX:PLX: 63.81 )
Ranked among companies with meaningful ROA (%) only.
AMEX:PLX' s ROA (%) Range Over the Past 10 Years
Min: -67.46  Med: -36.59 Max: 66.1
Current: 63.81
-67.46
66.1
ROC (Joel Greenblatt) (%) -312.59
AMEX:PLX's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. AMEX:PLX: -312.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMEX:PLX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -988.83  Med: -225.65 Max: -67
Current: -312.59
-988.83
-67
Revenue Growth (3Y)(%) -50.50
AMEX:PLX's Revenue Growth (3Y)(%) is ranked lower than
86% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. AMEX:PLX: -50.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMEX:PLX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 323.2
Current: -50.5
0
323.2
EBITDA Growth (3Y)(%) 36.90
AMEX:PLX's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AMEX:PLX: 36.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AMEX:PLX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.3  Med: -11.2 Max: 83
Current: 36.9
-53.3
83
EPS Growth (3Y)(%) 30.70
AMEX:PLX's EPS Growth (3Y)(%) is ranked higher than
83% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. AMEX:PLX: 30.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AMEX:PLX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.5  Med: -5.8 Max: 55
Current: 30.7
-49.5
55
» AMEX:PLX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

PLX Guru Trades in

Q4 2015

PLX Guru Trades in Q4 2015

Jim Simons 20,933 sh (New)
» More
Q1 2016

PLX Guru Trades in Q1 2016

Jim Simons 54,900 sh (+162.27%)
» More
Q2 2016

PLX Guru Trades in Q2 2016

Jim Simons 102,900 sh (+87.43%)
» More
» Details

Insider Trades

Latest Guru Trades with PLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CYTR, OTCPK:MTFBF, NAS:OCRX, NAS:DNAI, NAS:GLMD, OTCPK:TPIVD, NAS:CALA, NAS:EARS, NAS:CASI, NAS:TTHI, NAS:PBMD, OTCPK:DMYDY, OTCPK:NURPF, NAS:RPRX, NAS:NWBO, NAS:IPCI, OTCPK:PTIX, NAS:MTP, OTCPK:KBIO, OTCPK:DYAI » details
Traded in other countries:PBD.Germany, PLX.Israel,
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.

Protalix BioTherapeutics Inc was originally incorporated in the State of Florida in April 1992. It is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx. Using its ProCellEx system, it is developing a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Its initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company has developed ElelysoTM, its first drug product, ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The Company is now also applying the properties of its ProCellEx system for the oral delivery of therapeutic proteins. The Company relies on a single approved supplier for certain materials relating to the current expression of its proprietary biotherapeutic proteins through ProCellEx. It faces competition from companies with approved treatments of Gaucher disease. Some such companies include iBio, Inc., Medicago Inc., and Greenovation Biotech GmbH. The Company has 94 pending patent applications and one joint pending patent application with a third party. The Company is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar authorities in other countries.

Ratios

vs
industry
vs
history
P/E(ttm) 1.08
PLX's P/E(ttm) is ranked higher than
97% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. PLX: 1.08 )
Ranked among companies with meaningful P/E(ttm) only.
PLX' s P/E(ttm) Range Over the Past 10 Years
Min: 1.05  Med: 1.36 Max: 1.69
Current: 1.08
1.05
1.69
Price/Owner Earnings (ttm) 3.29
PLX's Price/Owner Earnings (ttm) is ranked higher than
92% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. PLX: 3.29 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PLX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.29  Med: 17.68 Max: 33.92
Current: 3.29
3.29
33.92
Current Ratio 5.90
PLX's Current Ratio is ranked higher than
59% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. PLX: 5.90 )
Ranked among companies with meaningful Current Ratio only.
PLX' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 5.45 Max: 72.77
Current: 5.9
1.02
72.77
Quick Ratio 5.37
PLX's Quick Ratio is ranked higher than
57% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. PLX: 5.37 )
Ranked among companies with meaningful Quick Ratio only.
PLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 5.19 Max: 72.77
Current: 5.37
0.96
72.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.20
PLX's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. PLX: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PLX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -539.3  Med: -5 Max: 14
Current: -2.2
-539.3
14

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -42.70
PLX's Earnings Yield (Greenblatt) (%) is ranked lower than
84% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. PLX: -42.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PLX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -44.6  Med: 5037.85 Max: 12682.8
Current: -42.7
-44.6
12682.8

More Statistics

EPS (TTM) $ 0.53
Beta0.13
Short Percentage of Float0.91%
52-Week Range $0.56 - 1.44
Shares Outstanding (Mil)99.81

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 4 4
EPS ($) -0.45 -0.44 -0.39
EPS w/o NRI ($) -0.45 -0.44 -0.39
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for AMEX:PLX

Headlines

Articles On GuruFocus.com
Avago Technologies' Memory, FBAR, and Connectivity Business Will Take It Higher Oct 23 2014 
Weekly CFO Sells Highlight: AXP, CRAY, PLX, KMB, ITW, CATM, CAR May 07 2012 
Protalix BioTherapeutics Inc Reports Operating Results (10-K) Feb 23 2011 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Nov 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Oct 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Sep 08 2010 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 05 2010 
Protalix BioTherapeutics Inc (PLX) CEO and President David Aviezer sells 244,238 Shares Oct 21 2009 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 150,000 Shares Oct 19 2009 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 03 2009 

More From Other Websites
Plexure signs new customer Sep 22 2016
Notice of Annual Meeting of Shareholders Sep 15 2016
Initial Disclosure Notice Sep 14 2016
Protalix BioTherapeutics Announces Presentation of Results from the Phase I/II Clinical Trial of... Sep 07 2016
Protalix BioTherapeutics Announces Presentation of Results from the Phase I/II Clinical Trial of... Sep 07 2016
Plexure appoints Andrew Dalziel as Chief Financial Officer Sep 06 2016
Market Update - Plexure Group Aug 25 2016
Market Update –McDonald’s Canada rollout Aug 25 2016
Nomination of Directors Aug 25 2016
PROTALIX BIOTHERAPEUTICS, INC. Financials Aug 17 2016
Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for... Aug 10 2016
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Aug 10 2016
Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for... Aug 10 2016
Protalix reports 2Q loss Aug 08 2016
Protalix reports 2Q loss Aug 08 2016
Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results Aug 08 2016
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 08 2016
Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results Aug 08 2016
VML - Waivers from NZX Main Board Listing Rules Aug 01 2016
Update: VMob Group Limited Name Change Jul 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)